Thrive Earlier Detection is a cancer diagnostics company developing a liquid biopsy-based screening test to detect cancer in its earlier, pre-metastatic stages.

Thrive is developing a high-quality, affordable, “multi-cancer” test for healthy adults, to be administered by primary care physicians as part of routine medical care. This test will enable proactive cancer management that significantly prolongs and improves patient quality of life, saving hundreds of thousands of lives annually. The underlying technology, called CancerSEEK, was developed by Dr. Bert Vogelstein and his colleagues at Johns Hopkins, and is exclusively licensed by Thrive.